References
  1. Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020; 12: 3053-3094. doi: 10.18632/aging.102777
  2. Luo J, Gao B, Lin Z, Fan H, Ma W, Yu D, Yang Q, Tian J, Yang X, Li B. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.Front Oncol. 2022; 12:1010726. doi: 10.3389/fonc.2022.1010726
  3. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinom. N Engl J Med . 2020; 382:1894-1905. doi: 10.1056/NEJMoa1915745
  4. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat Rev Drug Disc . 2006; 5:835-44. doi: 10.1038/nrd2130
  5. Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. PharmGKB summary: sorafenib pathways, Pharmacogenet Genomics . 2017; 27:240-246. doi: 10.1097/FPC.0000000000000279
  6. Terada T, Noda S, Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther . 2015; 152:125-134. doi: 10.1016/j.pharmthera.2015.05.009
  7. Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten Years of Sorafenib in Hepatocellular Carcinoma: Are there any Predictive and/or Prognostic Markers? World J Gastroenterol . 2018; 24:4152-4163. doi: 10.3748/wjg.v24.i36.4152
  8. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020; 77:1745-1770. doi: 10.1007/s00018-019-03351-7
  9. Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL. ENOS Polymorphisms and Clinical Outcome in Advanced HCC Patients Receiving Sorafenib: Final Results of the ePHAS Study. Oncotarget 2016; 7:27988-27999. doi: 10.18632/oncotarget.8569
  10. Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G, Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E, Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M. Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Target Oncol . 2020; 15:115-126. doi: 10.1007/s11523-020-00698-x
  11. Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clin Cancer Res . 2020; 26:4485-4493. doi: 10.1158/1078-0432.CCR-19-3897
  12. Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P. DMET (Drug Metabolism Enzymes and Transporters): A pharmacogenomic platform for precision medicine. Oncotarget 2016; 8:54028-54050. doi: 10.18632/oncotarget.9927
  13. Arbitrio M, Scionti F, Di Martino MT, Caracciolo D, Pensabene L, Tassone P, Tagliaferri P. Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical. Practic Clin Transl Sci . 2021; 14: 113-119. doi: 10.1111/cts.12869
  14. Scionti F, Di Martino MT, Caracciolo D, Pensabene L, Tagliaferri P, Arbitrio M. Tools in Pharmacogenomics Biomarker Identification for Cancer Patients. Methods Mol Biol. 2022; 2401:1-12. doi: 10.1007/978-1-0716-1839-4_1
  15. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis . 2010; 30:52-60. doi: 10.1055/s-0030-1247132
  16. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.Hepatology . 2011; 53:1020-1022. doi: 10.1002/hep.24199
  17. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J. Hepatol. 56 (2012) 908-943. doi: 10.1016/j.jhep.2011.12.001
  18. Scionti FPL, Di Martino MT, Arbitrio M, Tagliaferri P. Ethical Perspectives on Pharmacogenomic Profiling. Elsevier. Amsterdam, The Netherlands, 2021.
  19. Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K, Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D, Pensabene L. Genetic variants associated with Fabry disease progression despite enzyme replacement therapy, Oncotarget . 2017; 8:107558-107564. doi: 10.18632/oncotarget.22505
  20. Scionti F, Agapito G, Caracciolo D, Riillo C, Grillone K, Cannataro M, Di Martino MT, Tagliaferri P, Tassone P, Arbitrio M. Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes. Cells . 2022; 11:189. doi: 10.3390/cells11020189
  21. Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P. Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study, Clin Pharmacol Ther. 2019; 106:422-431. doi: 10.1002/cpt.1391
  22. Cargnin S, Viana M, Sances G, Cantello R, Tassorelli C, Terrazzino S. Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura. J Clin Pharmacol . 2019; 59:288-294. doi: 10.1002/jcph.1320
  23. Du B, Zhang C, Yue L, Ren B, Zhao Q, Li D, He Y, Zhang W. Prediction model for the efficacy of folic acid therapy on hyperhomocysteinaemia based on genetic risk score methods. Br J Nutr . 2019; 122:39-46. doi: 10.1017/S0007114519000783
  24. Gagno S, D’Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. Clin Breast Cancer . 2019; 19:137-145. doi: 10.1016/j.clbc.2018.11.009
  25. Faloppi L, Casadei Gardini A, Masi G, Silvestris N, Loretelli C, Ulivi P, Vivaldi C, Bianconi M, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Scartozzi M, Cascinu S. Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α Final results of the ALICE-2 study. J Clin Oncol . 2016; 34:280. doi: 10.1200/jco.2016.34.4_suppl.280
  26. Guzzi PH, Agapito G, Di Martino MT, Arbitrio M, Tassone P, Tagliaferri P, Cannataro M. DMET-Analyzer: automatic analysis of Affymetrix DMET Data. BMC Bioinformatics . 2012; 13:258. doi: 10.1186/1471-2105-13-258
  27. Agapito G, Milano M, Cannataro M. A statistical network pre-processing method to improve relevance and significance of gene lists in microarray gene expression studies. BMC Bioinformatics . 2022; 23:1-20. doi: 10.1186/s12859-022-04936-z
  28. Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res . 2019; 47:581-589. doi: 10.1093/nar/gky1037
  29. Lee S, Liu Y, Li J, Friedman C, Lussier YA. Discovery of protein interaction networks shared by diseases. Pac Symp Biocomput . 2007; 76-87.
  30. Paul S, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res . 2003; 13:2498-2504. doi: 10.1101/gr.1239303
  31. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. Cytohubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4(Suppl 4):S11 doi: 10.1186/1752-0509-8-S4-S11
  32. Agapito G, Cannataro U. Using BioPAX-Parser (BiP) to enrich lists of genes or proteins with pathway data. BMC Bioinformatics . 2021; 22:1-35. doi: 10.1186/s12859-021-04297-z
  33. Rahmati S, Abovsky M, Pastrello CM, Kotlyar M, Lu R, Cumbaa CA, Rahman P, Chandran V, Jurisica I. pathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. Nucleic Acids Res . 2020; 48:479-488. doi: 10.1093/nar/gkz989
  34. Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int . 2021; 21: 208 doi: 10.1186/s12935-021-01924-w
  35. Kobayashi K, Higai K, Matsuo K, Bannai Y, Horie H, Otakara Y, Li W, Koike K, Yanagino S, Watanabe K, Yoshio T, Wakui N, Nagai H. Quantitative Measurements of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Int J Res Stud Med Health Sci. 2018; 3:14-19.
  36. Ruggiero D, Dalmasso C, Nutile T, Sorice R, Dionisi L, Aversano M, Bröet P, Leutenegger AL, Bourgain C, Ciullo M. Genetics of VEGF serum variation in human isolated populations of cilento: importance of VEGF polymorphisms. PLoS One . 2011; 6:e16982. doi: 10.1371/journal.pone.0016982
  37. Al-Habboubi HH, Mahdi N, Abu-Hijleh TM, Abu-Hijleh FM, Sater MS, Almawi WY. The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease, Eur J Haematol . 2012; 89:403-409. doi: 10.1111/ejh.12003
  38. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med . 2008; 24:378-390. doi: 10.1056/NEJMoa0708857
  39. Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori . 2018; 104:476-479. doi: 10.5301/tj.5000704
  40. Fang X, Liu Y, Xiao W, Zhao N, Zhu C, Yu D, Zhao Y. Prognostic SLC family genes promote cell proliferation, migration, and invasion in hepatocellular carcinoma. Acta Biochim Biophys Sin. (Shanghai) . 2021; 53:1065-1075. doi: 10.1093/abbs/gmab076
  41. Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J, Pastor-Anglada M. Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Front Pharmacol . 2016; 7:175. doi: 10.3389/fphar.2016.00175
  42. Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Biomed Pharmacother . 2019; 114:108864. doi: 10.1016/j.biopha.2019.108864
  43. Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology . 2013; 58:1065-1073. doi: 10.1002/hep.26425
  44. Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla R, Marin JJ. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.Oncotarget . 2017; 8:15846-15857. doi: 10.18632/oncotarget.15029
  45. Liu X, Huang R, Liu X, You H, Kong F, Tang R. Prognostic implications of alcohol dehydrogenases in hepatocellular carcinoma. BMC Cancer . 2020; 20:1204. doi: 10.1186/s12885-020-07689-1
  46. Osanai M, Lee GH. Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes . 2014; 7:697. doi: 10.1186/1756-0500-7-697
  47. Osanai M, Lee GH. The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells. Oncol Rep . 2015; 34:850-858. doi: 10.3892/or.2015.4042
  48. Yu Y, Wang Y, Zou Y, Yu Y. CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and In Vitro Experiments. Dis Markers . 2022; 2022:5286820. doi: 10.1155/2022/5286820
  49. Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N, Toriguchi K, Hatano E, Endo K, Hirooka Y, Shiota G. Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells. J Hepatol . 2013; 59:1037-1044. doi: 10.1016/j.jhep.2013.06.024
  50. Lotan R. Retinoids as modulators of tumor cells invasion and metastasis. Semin Cancer Biol. 199;1 2: 197-208.